SG11202111740PA - Stable, low-viscosity antibody formulations and uses thereof - Google Patents

Stable, low-viscosity antibody formulations and uses thereof

Info

Publication number
SG11202111740PA
SG11202111740PA SG11202111740PA SG11202111740PA SG11202111740PA SG 11202111740P A SG11202111740P A SG 11202111740PA SG 11202111740P A SG11202111740P A SG 11202111740PA SG 11202111740P A SG11202111740P A SG 11202111740PA SG 11202111740P A SG11202111740P A SG 11202111740PA
Authority
SG
Singapore
Prior art keywords
formulation
hours
antibody
days
months
Prior art date
Application number
SG11202111740PA
Other languages
English (en)
Inventor
Atul Saluja
Manjori Ganguly
Kelvin Rembert
Yatin Gokarn
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202111740P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202111740PA publication Critical patent/SG11202111740PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202111740PA 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof SG11202111740PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
EP20305145 2020-02-17
PCT/EP2020/061340 WO2020216847A1 (en) 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof

Publications (1)

Publication Number Publication Date
SG11202111740PA true SG11202111740PA (en) 2021-11-29

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111740PA SG11202111740PA (en) 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
MA55750A (fr) 2022-03-02
AU2020262231A1 (en) 2021-12-16
KR20220004104A (ko) 2022-01-11
IL287435A (en) 2021-12-01
CA3137464A1 (en) 2020-10-29
EP3958896A1 (en) 2022-03-02
JP2022530050A (ja) 2022-06-27
WO2020216847A1 (en) 2020-10-29
CN114286690A (zh) 2022-04-05
BR112021021099A2 (pt) 2021-12-14
MX2021012968A (es) 2022-01-18
JP7671697B2 (ja) 2025-05-02
TW202108171A (zh) 2021-03-01
JP2025087851A (ja) 2025-06-10
US20220218607A1 (en) 2022-07-14
CO2021015561A2 (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US20220218607A1 (en) Stable, low-viscosity antibody formulations and uses thereof
TWI860988B (zh) 低ph藥物製劑
US10588976B2 (en) Anti-CD40 antibody formulation
JP7126454B2 (ja) 医薬組成物
RU2653447C2 (ru) Стабилизированные содержащие антитела жидкие композиции
AU2014295052B2 (en) Stabilized antibody compositions
JP4583762B2 (ja) ポリペプチド製剤
CN101820912B (zh) 抗体制剂
TWI682788B (zh) 包含ｇｍ－ｃｓｆ中和化合物之液態調配物
US12350340B2 (en) Viscosity reduction of highly concentrated protein formulations
TW200934792A (en) Antibody formulation
TW201438735A (zh) 包括ｇｍ－ｃｓｆ中和化合物之液態配方
CN111417385A (zh) 减少喷雾干燥的蛋白质制剂的重构时间的方法
EP4142789A1 (en) Pharmaceutical formulation
CN116510006A (zh) 抗trbv9抗体的药物组合物及其用途